SAN DIEGO, Dec. 22 /PRNewswire-FirstCall/ -- dj Orthopedics, Inc., (NYSE: DJO), announced today that it intends to file a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
Once the shelf registration statement has been filed and subsequently declared effective by the Securities and Exchange Commission, it will allow dj Orthopedics to issue, from time to time, up to $85,000,000 of common stock and will also allow selling stockholders to sell, from time to time, up to 4,000,000 shares of dj Orthopedics' outstanding common stock. The nature and terms of any offering will be set forth in a supplemental filing with the Securities and Exchange Commission.
dj Orthopedics currently intends to use the net proceeds from the sale of common stock by it for general corporate purposes, including repaying or refinancing debt or other corporate obligations, acquisitions, working capital, capital expenditures, repurchases and redemptions of securities, general and administrative expenses and/or any other purpose permitted under its senior secured credit facility.
The registration statement relating to these securities will be filed with the Securities and Exchange Commission and has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer of these securities will be made solely by means of the prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering.
About dj Orthopedics
dj Orthopedics is a global orthopedic sports medicine company focused on the design, manufacture and marketing of products and services that regenerate and rehabilitate soft tissue and bone after trauma, help protect against injury and treat osteoarthritis of the knee. Its broad range of over 600 rehabilitation products, many of which are based on proprietary technologies, includes rigid knee braces, soft goods, specialty and other complementary orthopedic products such as cold
therapy and pain management systems. The Company's regeneration products consist of two bone growth stimulation devices, the OL1000, approved by the FDA in 1994, which utilizes patented Combined Magnetic Field technology to deliver a highly specific, low-energy signal for the non-invasive treatment of an established nonunion fracture acquired secondary to trauma,
excluding vertebrae and all flat bones, and SpinaLogic®, a state-of-the-art device used as an adjunct to primary lumbar spinal fusion surgery for one or two levels, approved by the FDA in late 1999. The Company's products provide solutions for orthopedic professionals and their patients throughout the patient's continuum of care.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including those related to dj Orthopedics' ability to raise financing. For a discussion of such risks and uncertainties, which could cause actual results to differ significantly from those expressed in or implied by such forward-looking statements, please refer to our Annual Report on Form 10-K for the 2002 calendar year, filed on March 28, 2003 with the Securities and Exchange Commission.
SOURCE dj Orthopedics, Inc.
-0- 12/22/2003
CO: dj Orthopedics, Inc.
ST: California
IN: HEA SPM MTC BIO
SU:
LP
-- LAM071 --
3534 12/22/2003 13:52 EST http://www.prnewswire.com
Company Investor/Media Contact:
DJO Incorporated
Mark Francois
Director of Corporate Communications & Investor Relations
760-734-4766
